A Phase 2 interventional study of TTAX03 and Saline (NaCl 0,9 %) (placebo) in Dry Eye, Dry Eye Disease (DED) and Dry Eye Disease With Severe Keratitis, sponsored by BioTissue Holdings, Inc. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by BioTissue Holdings, Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.
Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 218th largest by enrollment of the 473 interventional ones that give a count, is one of 32 that started in 2024, is one of 97 in phase 2, and was the 481st registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:
Scott & Christie and Associates, PC · Sites in United States
Ages 18+
Bausch & Lomb Incorporated · Sites in United States
Ages 18+
Alcon Research · Sites in United States
Ages 22+ · Healthy volunteers
Cleveland Eye Clinic · Sites in United States
Ages 50–75
Eye Research Associates, LLC · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
544 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 132 · Phase 3 95 · Phase 4 116
First in 1997; this study’s year is marked. 32 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 60 across the 473 interventional studies, 80 across the 64 observational. Of the 439 that completed or were terminated, 232 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
330 of 544 have an industry lead sponsor. The 10 most frequent:
BioTissue Holdings, Inc is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.
BioTissue Holdings, Inc has 3 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
31 of the studies in Dry Eye Syndromes with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548632Phase 3OculisA Clinical Study Evaluating Licaminlimab for Dry Eye Disease | 2026-12 |
| NCT07281950Center for Sight Las VegasInvestigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) | 2026-11-30 |
| NCT07566975Neuro-Ophthalmology of TexasReal-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study | 2026-11-30 |
| NCT07768735Alcon ResearchUNITY DX Cornea Study | 2026-12 |
| NCT07928986Cleveland Eye ClinicA Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 544 studies in Dry Eye Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this randomized, controlled, multicenter study is to evaluate the safety and efficacy of TTAX03 in participants with mild to moderate DED.
The primary question it aims to answer is if TTAX03 is safe. The secondary is the effectiveness.
Researchers will compare 10mg of TTAX03 reconstituted in 150, 300, or 600 uL saline to the saline control group to look at effectiveness.
Participants will be randomized to a treatment group one time and be evaluated at 5 different study visits.
The purpose of this randomized, controlled, multicenter study is to evaluate the safety and efficacy of TTAX03 in participants with mild to moderate DED. After confirmation of inclusion and exclusion criteria, all eligible patients will be randomized in a 1:1:1:1 ratio to receive one of the three doses of TTAX03 (10 mg of TTAX03 reconstituted in 150, 300, or 600 uL saline, i.e., subgroup A, B, and C, respectively) or to the saline control group (subgroup D). For all four groups, the same volume of reconstituted solution will be applied into the concave bowl of a bandage contact lens and inserted into the eye. The more severe eye will serve as the study eye, which meets inclusion and exclusion criteria. The treatment period is 5 days of continuous bandage contact lens wear. Safety follow-up without further treatment will continue for twelve weeks. After baseline (day 1) and completion of treatment, enrolled patients will be evaluated for safety and efficacy at Day 6 ± 1, Day 29 ± 3, Day 57 ± 3, and Day 85 ± 3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For all four groups, 100 mL of reconstituted solution will be applied into the concave bowl of a bandage contact lens and inserted into the study eye.
Biological: TTAX03
For all four groups, 100 mL of reconstituted solution will be applied into the concave bowl of a bandage contact lens and inserted into the study eye.
Biological: TTAX03
For all four groups, 100 mL of reconstituted solution will be applied into the concave bowl of a bandage contact lens and inserted into the study eye.
Biological: TTAX03
For all four groups, 100 mL of reconstituted solution will be applied into the concave bowl of a bandage contact lens and inserted into the study eye.
Biological: Saline (NaCl 0,9 %) (placebo)
Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord
300 mL Sterile, preservative free 0.9% NaCl
Determine 12 week ocular and general safety after application of TTAX03.
Incidence and nature of treatment emergent adverse events (TEAE) between TTAX03 and saline.
Time frame: 12 weeks
Proportion of participants who show complete resolution of superficial punctate keratopathy, i.e., absence of corneal fluorescein staining, on Day 6 by group.
Determine the relationship between TTAX03 doses and efficacy per changes from baseline in complete resolution of superficial punctate keratopathy (defined by corneal fluorescein staining) at Day 6 when compared to the saline control.
Time frame: Day 6
Mean change from baseline to Day 6 in corneal fluorescein staining (National Eye Institute (NEI) score) by group.
Examine the relationship between TTAX03 doses and changes from baseline in corneal epithelial staining at Day 6 when compared to the saline control.
Time frame: Baseline to Day 6
Proportion of participants with clinically meaningful reduction in corneal fluorescein staining (NEI ≥ 3) from baseline to Day 6 by group.
Examine the relationship between TTAX03 doses and clinically meaningful changes from baseline vs. saline in corneal staining during the follow up to 12 weeks.
Time frame: Baseline to Day 6
Proportion of participants with clinically meaningful reduction in corneal fluorescein staining (NEI ≥ 3) from baseline to Day 29 by group.
Examine the relationship between TTAX03 doses and clinically meaningful changes from baseline vs. saline in corneal staining during the follow up to 12 weeks.
Time frame: Baseline to Day 29
Proportion of participants with clinically meaningful reduction in corneal fluorescein staining (NEI ≥ 3) from baseline to Day 57 by group.
Examine the relationship between TTAX03 doses and clinically meaningful changes from baseline vs. saline in corneal staining during the follow up to 12 weeks.
Time frame: Baseline to Day 57
Proportion of participants with clinically meaningful reduction in corneal fluorescein staining (NEI ≥ 3) from baseline to Day 85 by group.
Examine the relationship between TTAX03 doses and clinically meaningful changes from baseline vs. saline in corneal staining during the follow up to 12 weeks.
Time frame: Baseline to Day 85
Mean change in dry eye symptoms (measured by OSDI) from baseline on Day 6 by group.
Examine the relationship between TTAX03 doses and change of dry eye symptoms from baseline when compared to saline at Day 6.
Time frame: Baseline to Day 6
Mean change in dry eye symptoms (measured by VAS) from baseline on Day 6 by group.
Examine the relationship between TTAX03 doses and change of dry eye symptoms from baseline when compared to saline at Day 6.
Time frame: Baseline to Day 6
Mean change from baseline in BCVA (logMAR) measured by ETDRS chart on Day 6 by group.
Examine the relationship between TTAX03 doses and change of best corrected visual acuity (BCVA) from baseline when compared to saline at Day 6.
Time frame: Baseline to Day 6
Proportion of participants who show complete resolution of superficial punctate keratopathy, i.e., absence of corneal fluorescein staining, on Day 29 by group.
Examine the relationship between TTAX03 doses and percentages of participants showing complete resolution of corneal staining from baseline when compared to saline during the follow up 12 weeks.
Time frame: Day 29
Proportion of participants who show complete resolution of superficial punctate keratopathy, i.e., absence of corneal fluorescein staining, on Day 57 by group.
Examine the relationship between TTAX03 doses and percentages of participants showing complete resolution of corneal staining from baseline when compared to saline during the follow up 12 weeks.
Time frame: Day 57
Proportion of participants who show complete resolution of superficial punctate keratopathy, i.e., absence of corneal fluorescein staining, on Day 85 by group.
Examine the relationship between TTAX03 doses and percentages of participants showing complete resolution of corneal staining from baseline when compared to saline during the follow up 12 weeks.
Time frame: Day 85
Mean change from baseline in corneal fluorescein staining (National Eye Institute (NEI) score) on Day 29 by group.
Examine the relationship between TTAX03 doses and change of corneal epithelial staining from baseline between when compared to saline during the follow up to 12 weeks.
Time frame: Baseline to Day 29
Mean change from baseline in corneal fluorescein staining (National Eye Institute (NEI) score) on Day 57 by group.
Examine the relationship between TTAX03 doses and change of corneal epithelial staining from baseline between when compared to saline during the follow up to 12 weeks.
Time frame: Baseline to Baseline to Day 57
Mean change from baseline in corneal fluorescein staining (National Eye Institute (NEI) score) on Day 85 by group.
Examine the relationship between TTAX03 doses and change of corneal epithelial staining from baseline between when compared to saline during the follow up to 12 weeks.
Time frame: Baseline to Baseline to Day 85
Mean change in dry eye symptoms (measured by OSDI) from baseline on Day 29 by group.
Examine the relationship between TTAX03 doses and change of ocular dry eye symptoms from baseline when compared to saline during the follow up to 12 weeks.
Time frame: Baseline to Day 29
Mean change in dry eye symptoms (measured by OSDI) from baseline on Day 57 by group.
Examine the relationship between TTAX03 doses and change of ocular dry eye symptoms from baseline when compared to saline during the follow up to 12 weeks.
Time frame: Baseline to Day 57
Mean change in dry eye symptoms (measured by OSDI) from baseline on Day 85 by group.
Examine the relationship between TTAX03 doses and change of ocular dry eye symptoms from baseline when compared to saline during the follow up to 12 weeks.
Time frame: Baseline to Day 85
Mean change in dry eye symptoms (measured by VAS) from baseline on Day 29 by group.
Examine the relationship between TTAX03 doses and change of ocular dry eye symptoms from baseline when compared to saline during the follow up to 12 weeks.
Time frame: Baseline to Day 29
Mean change in dry eye symptoms (measured by VAS) from baseline on Day 57 by group.
Examine the relationship between TTAX03 doses and change of ocular dry eye symptoms from baseline when compared to saline during the follow up to 12 weeks.
Time frame: Baseline to Day 57
Mean change in dry eye symptoms (measured by VAS) from baseline on Day 85 by group.
Examine the relationship between TTAX03 doses and change of ocular dry eye symptoms from baseline when compared to saline during the follow up to 12 weeks.
Time frame: Baseline to Day 85
Mean change from baseline in BCVA (logMAR) measured by ETDRS chart on Days 29 by group.
Examine the relationship between TTAX03 doses and change of BCVA from baseline when compared to saline during the follow up to 12 weeks.
Time frame: Day 29
Mean change from baseline in BCVA (logMAR) measured by ETDRS chart on Day 57 by group.
Examine the relationship between TTAX03 doses and change of BCVA from baseline when compared to saline during the follow up to 12 weeks.
Time frame: Day 57
Mean change from baseline in BCVA (logMAR) measured by ETDRS chart on Day 85 by group.
Examine the relationship between TTAX03 doses and change of BCVA from baseline when compared to saline during the follow up to 12 weeks.
Time frame: Day 85
Ran from Dec 2024 to primary completion in Jan 2026, 13 months.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 13 months is above that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TTAX-03
BioTissue Holdings, Inc